Literature DB >> 24664661

Involvement of adrenomedullin in spinal glial activation following chronic administration of morphine in rats.

X Zeng1, M Y Lin, D Wang, Y Zhang, Y Hong.   

Abstract

BACKGROUND: Adrenomedullin (AM) belongs to the calcitonin gene-related peptide (CGRP) family. Our previous studies show that chronic exposure to morphine increases spinal AM bioactivity, contributing to the development and maintenance of morphine tolerance. This study investigated the possible involvement of AM in morphine-evoked gliosis.
METHODS: Real-time polymerase chain reaction was performed to determine interleukin-1β (IL-1β), IL-6 and tumour necrosis factor-α (TNF-α) mRNAs in the spinal dorsal horn and cultured sensory ganglion explants. Immunohistochemistry was performed to identify spinal microglia and astrocytes.
RESULTS: Repetitive intrathecal (i.t.) injection of morphine (20 μg) increased the expression of IL-1β, IL-6 and TNF-α mRNAs in the spinal dorsal horn. The co-administration of the selective AM receptor antagonist AM22-52 (36 μg) markedly attenuated chronic morphine-evoked increase in IL-1β and IL-6, but not TNF-α, mRNA levels. Exposure of cultured dorsal root ganglion (DRG) explants to morphine (3.3 μmol/L) for 6 days up-regulated IL-1β and IL-6 mRNA expressions. The depletion of AM gene using small interfering RNA (siRNA) approach abolished morphine-evoked increase in IL-1β and IL-6 syntheses in the cultured DRG. The blockade of AM receptors by i.t. AM22-52 also inhibited chronic morphine-evoked cell hypertrophy of microglia and astrocytes as well as an increase in OX-42 and GFAP (glial fibrillary acidic protein) immunoreactivities. Furthermore, the 6-day treatment with AM (10 μg, i.t.) induced morphological changes of microglia and astrocytes as well as an increase in IL-1β, IL-6 and TNF-α mRNA levels in the spinal dorsal horn.
CONCLUSION: The present study supports the idea that up-regulation of the pronociceptive mediator AM can recruit spinal glial cells, resulting in an increase in cytokines during chronic use of morphine.
© 2014 European Pain Federation - EFIC®

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664661     DOI: 10.1002/j.1532-2149.2014.493.x

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  12 in total

Review 1.  Regulatory mechanisms and therapeutic potential of microglial inhibitors in neuropathic pain and morphine tolerance.

Authors:  Er-Rong Du; Rong-Ping Fan; Li-Lou Rong; Zhen Xie; Chang-Shui Xu
Journal:  J Zhejiang Univ Sci B       Date:  2020 Mar.       Impact factor: 3.066

2.  Contribution of adrenomedullin to the switch of G protein-coupled μ-opioid receptors from Gi to Gs in the spinal dorsal horn following chronic morphine exposure in rats.

Authors:  Dongmei Wang; Juan Zeng; Qi Li; Jianzhong Huang; Réjean Couture; Yanguo Hong
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

Review 3.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

Review 4.  Non-coding RNAs and neuroprotection after acute CNS injuries.

Authors:  Raghavendar Chandran; Suresh L Mehta; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2017-01-26       Impact factor: 3.921

Review 5.  Adrenomedullin, a Novel Target for Neurodegenerative Diseases.

Authors:  Hilda Ferrero; Ignacio M Larrayoz; Francisco J Gil-Bea; Alfredo Martínez; María J Ramírez
Journal:  Mol Neurobiol       Date:  2018-03-29       Impact factor: 5.590

6.  Clinical Observation of the Effects of Oral Opioid on Inflammatory Cytokines and Gut Microbiota in Patients with Moderate to Severe Cancer Pain: A Retrospective Cohort Study.

Authors:  Hanxiang Wang; Juan Luo; Xu Chen; Huiping Hu; Shijun Li; Yu Zhang; Chen Shi
Journal:  Pain Ther       Date:  2022-04-18

Review 7.  Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases.

Authors:  Lila Carniglia; Delia Ramírez; Daniela Durand; Julieta Saba; Juan Turati; Carla Caruso; Teresa N Scimonelli; Mercedes Lasaga
Journal:  Mediators Inflamm       Date:  2017-01-05       Impact factor: 4.711

Review 8.  Targeting Cytokines for Morphine Tolerance: A Narrative Review.

Authors:  Dai-Qiang Liu; Ya-Qun Zhou; Feng Gao
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

9.  Development of chimeric and bifunctional antagonists for CLR/RAMP receptors.

Authors:  Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

Review 10.  Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.

Authors:  Tayla A Rees; Erica R Hendrikse; Debbie L Hay; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2021-07-27       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.